| | | | | Product | Package Size | EFP | CP | SB | DC | Composition | Registr. Holder | Category | | | | |
---|
|
December 2023 - 69 products |
|
| | IP | CI | | Azelastin Fluticason Spirig HC Nasenspray | 25 ml | 13.58 | 31.20 | 10 % | | | Spirig HealthCare AG | B / SL / SG | FB | | G | |
L | | IP | CI | | Bupropion XR Sandoz 150 mg | 30 | 12.83 | 30.35 | 10 % | | Delayed release tablets: Bupropioni Hydrochloridum 150 mg | Sandoz Pharmaceuticals AG | B / SL / SG | FB | | G | |
L | | IP | | | Bupropion XR Sandoz 300 mg | 30 | 21.04 | 39.30 | 10 % | | Delayed release tablets: Bupropioni Hydrochloridum 300 mg | Sandoz Pharmaceuticals AG | B / SL / SG | FB | | G | |
L | | IP | CI | | Perindopril Amlodipin Indapamid Spirig HC 5 mg/5 mg/1,25 mg | 30 | 15.22 | 33.05 | 10 % | | Coated tablets: 3 Active Agents | Spirig HealthCare AG | B / SL / SG | FB | | G | |
L | | IP | CI | | Perindopril Amlodipin Indapamid Spirig HC 5 mg/5 mg/1,25 mg | 90 | 38.81 | 58.80 | 10 % | | Coated tablets: 3 Active Agents | Spirig HealthCare AG | B / SL / SG | FB | | G | |
L | | IP | | | Perindopril Amlodipin Indapamid Spirig HC 5 mg/10 mg/1,25 mg | 30 | 15.22 | 33.05 | 10 % | | Coated tablets: 3 Active Agents | Spirig HealthCare AG | B / SL / SG | FB | | G | |
L | | IP | | | Perindopril Amlodipin Indapamid Spirig HC 5 mg/10 mg/1,25 mg | 90 | 38.81 | 58.80 | 10 % | | Coated tablets: 3 Active Agents | Spirig HealthCare AG | B / SL / SG | FB | | G | |
L | | IP | | | Perindopril Amlodipin Indapamid Spirig HC 10 mg/5 mg/2,5 mg | 30 | 15.22 | 33.05 | 10 % | | Coated tablets: 3 Active Agents | Spirig HealthCare AG | B / SL / SG | FB | | G | |
L | | IP | | | Perindopril Amlodipin Indapamid Spirig HC 10 mg/5 mg/2,5 mg | 90 | 38.81 | 58.80 | 10 % | | Coated tablets: 3 Active Agents | Spirig HealthCare AG | B / SL / SG | FB | | G | |
L | | IP | | | Perindopril Amlodipin Indapamid Spirig HC 10 mg/10 mg/2,5 mg | 30 | 15.22 | 33.05 | 10 % | | Coated tablets: 3 Active Agents | Spirig HealthCare AG | B / SL / SG | FB | | G | |
L | | IP | | | Perindopril Amlodipin Indapamid Spirig HC 10 mg/10 mg/2,5 mg | 90 | 38.81 | 58.80 | 10 % | | Coated tablets: 3 Active Agents | Spirig HealthCare AG | B / SL / SG | FB | | G | |
L | | IP | CI | | Rivaroxaban Viatris vascular 2,5 mg | 56 | 26.83 | 45.60 | 10 % | | Coated tablets: Rivaroxabanum 2.5 mg | Viatris Pharma GmbH | B / SL / SG | FB | | G | |
L | | IP | CI | | Rivaroxaban Viatris vascular 2,5 mg | 196 | 93.92 | 118.55 | 10 % | | Coated tablets: Rivaroxabanum 2.5 mg | Viatris Pharma GmbH | B / SL / SG | FB | | G | |
| | IP | CI | | Dabigatran Spirig HC 110 mg | 60 | 40.97 | 60.95 | 10 % | | Capsules: Dabigatranum Etexilatum 110 mg | Spirig HealthCare AG | ● B / SL / SG | FB | | G | |
| | IP | CI | | Dabigatran Spirig HC 110 mg | 180 | 122.90 | 150.10 | 10 % | | Capsules: Dabigatranum Etexilatum 110 mg | Spirig HealthCare AG | B / SL / SG | FB | | G | |
| | IP | | | Dabigatran Spirig HC 150 mg | 60 | 40.97 | 60.95 | 10 % | | Capsules: Dabigatranum Etexilatum 150 mg | Spirig HealthCare AG | B / SL / SG | FB | | G | |
| | IP | | | Dabigatran Spirig HC 150 mg | 180 | 122.90 | 150.10 | 10 % | | Capsules: Dabigatranum Etexilatum 150 mg | Spirig HealthCare AG | B / SL / SG | FB | | G | |
| | IP | CI | | Travo-Vision SDU 40 ug / ml | 30 x 0.2 ml | 9.93 | 27.20 | 10 % | | Augentropfen im Einzeldosisbehältnis: Travoprostum | OmniVision AG | B / SL / SG | FB | | G | |
| | IP | CI | | Travo-Vision SDU 40 ug / ml | 90 x 0.2 ml | 28.30 | 47.20 | 10 % | | Augentropfen im Einzeldosisbehältnis: Travoprostum | OmniVision AG | B / SL / SG | FB | | G | |
L | | IP | CI | | Hemgenix 1x10 e13 gc/mL | | 2687096.87 | 2757269.20 | 10 % | | | CSL Behring AG | A / SL | FB | | G | |
L | | IP | CI | | Hemgenix 1x10 e13 gc/mL | 13 | 2687096.87 | 2757269.20 | 10 % | | | CSL Behring AG | A / SL | FB | | G | |
L | | IP | CI | | Hemgenix 1x10 e13 gc/mL | 25 | 2687096.87 | 2757269.20 | 10 % | | | CSL Behring AG | A / SL | FB | | G | |
L | | IP | CI | | Hemgenix 1x10 e13 gc/mL | 37 | 2687096.87 | 2757269.20 | 10 % | | | CSL Behring AG | A / SL | FB | | G | |
| | IP | CI | | Bonjesta 20 mg / 20 mg | 20 | 28.30 | 47.20 | 10 % | | Tablette mit veränderter Wirkstofffreisetzung: 2 Active Agents | Exeltis Suisse SA | B / SL | FB | | G | |
L | | IP | | | Beyfortus 50 mg/0.5 ml | | 350.00 | 395.60 | 10 % | | solution injectable en seringue préremplie: Nirsevimabum 50mg / 0.5ml | Sanofi-Aventis (Suisse) SA | A / SL | FB | | G | |
L | | IP | | | Beyfortus 100 mg/1 ml | | 350.00 | 395.60 | 10 % | | solution injectable en seringue préremplie: Nirsevimabum 100 mg/ml | Sanofi-Aventis (Suisse) SA | A / SL | FB | | G | |
| | IP | | | Elucirem 0.5 mmol/ml | 3 ml | PR | PR | k.A. | | | Guerbet AG | B | FB | | G | |
| | IP | | | Elucirem 0.5 mmol/ml | 7.5 ml | PR | PR | k.A. | | | Guerbet AG | B | FB | | G | |
| | IP | | | Elucirem 0.5 mmol/ml | 7.5 ml | PR | PR | k.A. | | | Guerbet AG | B | FB | | G | |
| | IP | | | Elucirem 0.5 mmol/ml | 10 ml | PR | PR | k.A. | | | Guerbet AG | B | FB | | G | |
| | IP | | | Elucirem 0.5 mmol/ml | 10 ml | PR | PR | k.A. | | | Guerbet AG | B | FB | | G | |
| | IP | | | Elucirem 0.5 mmol/ml | 15 ml | PR | PR | k.A. | | | Guerbet AG | B | FB | | G | |
| | IP | | | Elucirem 0.5 mmol/ml | 30 ml | PR | PR | k.A. | | | Guerbet AG | B | FB | | G | |
| | | | | Sugammadex Orion 200 mg/2 ml | | PR | PR | k.A. | | Injection solution: Sugammadexum 200mg / 2ml | Orion Pharma AG | B | FB | | G | |
| | | | | Sugammadex Orion 500 mg/5 ml | | PR | PR | k.A. | | Injection solution: Sugammadexum 500mg / 5ml | Orion Pharma AG | B | FB | | G | |
| | | | | Sugammadex Orion 200 mg/2 ml | 10 | PR | PR | k.A. | | Injection solution: Sugammadexum 200mg / 2ml | Orion Pharma AG | B | FB | | G | |
| | | | | Sugammadex Orion 500 mg/5 ml | 10 | PR | PR | k.A. | | Injection solution: Sugammadexum 500mg / 5ml | Orion Pharma AG | B | FB | | G | |
| | IP | CI | | Bupropion XR Sandoz 150 mg | 10 | PR | PR | k.A. | | Delayed release tablets: Bupropioni Hydrochloridum 150 mg | Sandoz Pharmaceuticals AG | B | FB | | G | |
| | | | | Apixaban Spirig HC 2.5 mg | 20 | PR | PR | k.A. | | Coated tablets: Apixabanum 2.5 mg | Spirig HealthCare AG | B | FB | | G | |
| | | | | Apixaban Spirig HC 2.5 mg | 60 | PR | PR | k.A. | | Coated tablets: Apixabanum 2.5 mg | Spirig HealthCare AG | B | FB | | G | |
| | | | | Apixaban Spirig HC 2.5 mg | 100 | PR | PR | k.A. | | Coated tablets: Apixabanum 2.5 mg | Spirig HealthCare AG | B | FB | | G | |
| | | | | Apixaban Spirig HC 2.5 mg | 168 | PR | PR | k.A. | | Coated tablets: Apixabanum 2.5 mg | Spirig HealthCare AG | B | FB | | G | |
| | | | | Apixaban Spirig HC 5 mg | 56 | PR | PR | k.A. | | Coated tablets: Apixabanum 5 mg | Spirig HealthCare AG | B | FB | | G | |
| | | | | Apixaban Spirig HC 5 mg | 100 | PR | PR | k.A. | | Coated tablets: Apixabanum 5 mg | Spirig HealthCare AG | B | FB | | G | |
| | | | | Apixaban Spirig HC 5 mg | 168 | PR | PR | k.A. | | Coated tablets: Apixabanum 5 mg | Spirig HealthCare AG | B | FB | | G | |
| | | | | Sitagliptin Metformin NOBEL 50 mg/500 mg | 56 | PR | PR | k.A. | | Coated tablets: 2 Active Agents | NOBEL Pharma Schweiz AG | B | FB | | G | |
| | | | | Sitagliptin Metformin NOBEL 50 mg/500 mg | 2 x 98 | PR | PR | k.A. | | Coated tablets: 2 Active Agents | NOBEL Pharma Schweiz AG | B | FB | | G | |
| | | | | Sitagliptin Metformin NOBEL 50 mg/850 mg | 56 | PR | PR | k.A. | | Coated tablets: 2 Active Agents | NOBEL Pharma Schweiz AG | B | FB | | G | |
| | | | | Sitagliptin Metformin NOBEL 50 mg/850 mg | 4 x 49 | PR | PR | k.A. | | Coated tablets: 2 Active Agents | NOBEL Pharma Schweiz AG | B | FB | | G | |
| | | | | Sitagliptin Metformin NOBEL 50 mg/1000 mg | 56 | PR | PR | k.A. | | Coated tablets: 2 Active Agents | NOBEL Pharma Schweiz AG | B | FB | | G | |
| | | | | Sitagliptin Metformin NOBEL 50 mg/1000 mg | 4 x 49 | PR | PR | k.A. | | Coated tablets: 2 Active Agents | NOBEL Pharma Schweiz AG | B | FB | | G | |
| | | | | Trederol 5000 I.E. | 20 | PR | PR | k.A. | | Coated tablets: Cholecalciferolum 5000 UI | Maras AG | B | FB | | G | |
| | | | | Trederol 5000 I.E. | 40 | PR | PR | k.A. | | Coated tablets: Cholecalciferolum 5000 UI | Maras AG | B | FB | | G | |
| | | | | Trederol 20000 I.E. | 5 | PR | PR | k.A. | | Coated tablets: Cholecalciferolum 20000 UI | Maras AG | B | FB | | G | |
| | IP | CI | | Veoza 45 mg | 30 | PR | PR | k.A. | | Coated tablets: Fezolinetantum 45 mg | Astellas Pharma AG | B | FB | | G | |
| | IP | CI | | Veoza 45 mg | 100 | PR | PR | k.A. | | Coated tablets: Fezolinetantum 45 mg | Astellas Pharma AG | B | FB | | G | |
| | IP | CI | | Levetiracetam Spirig HC 100 mg/ml | 300 ml | PR | PR | k.A. | | Solution (oral): Levetiracetamum 100 mg/ml | Spirig HealthCare AG | B | FB | | G | |
| | IP | CI | | Bonjesta 20 mg / 20 mg | 10 | PR | PR | k.A. | | Tablette mit veränderter Wirkstofffreisetzung: 2 Active Agents | Exeltis Suisse SA | B | FB | | G | |
| | IP | CI | | Bonjesta 20 mg / 20 mg | 30 | PR | PR | k.A. | | Tablette mit veränderter Wirkstofffreisetzung: 2 Active Agents | Exeltis Suisse SA | B | FB | | G | |
| | IP | CI | | Bonjesta 20 mg / 20 mg | 40 | PR | PR | k.A. | | Tablette mit veränderter Wirkstofffreisetzung: 2 Active Agents | Exeltis Suisse SA | B | FB | | G | |
| | IP | CI | | Bonjesta 20 mg / 20 mg | 50 | PR | PR | k.A. | | Tablette mit veränderter Wirkstofffreisetzung: 2 Active Agents | Exeltis Suisse SA | B | FB | | G | |
| | IP | CI | | Bonjesta 20 mg / 20 mg | 60 | PR | PR | k.A. | | Tablette mit veränderter Wirkstofffreisetzung: 2 Active Agents | Exeltis Suisse SA | B | FB | | G | |
| | IP | | | Xenpozyme 4 mg | | PR | PR | k.A. | | poudre pour solution à diluer pour perfusion: Olipudasum Alfa 4 mg | Sanofi-Aventis (Suisse) SA | A | FB | | G | |
| | IP | | | Xenpozyme 4 mg | 10 | PR | PR | k.A. | | poudre pour solution à diluer pour perfusion: Olipudasum Alfa 4 mg | Sanofi-Aventis (Suisse) SA | A | FB | | G | |
| | IP | | | Xenpozyme 20 mg | | PR | PR | k.A. | | poudre pour solution à diluer pour perfusion: Olipudasum Alfa 20 mg | Sanofi-Aventis (Suisse) SA | A | FB | | G | |
| | IP | | | Xenpozyme 20 mg | 10 | PR | PR | k.A. | | poudre pour solution à diluer pour perfusion: Olipudasum Alfa 20 mg | Sanofi-Aventis (Suisse) SA | A | FB | | G | |
| | IP | | | Beyfortus 50 mg/0.5 ml | | PR | PR | k.A. | | solution injectable en seringue préremplie: Nirsevimabum 50mg / 0.5ml | Sanofi-Aventis (Suisse) SA | A | FB | | G | |
| | IP | | | Beyfortus 100 mg/1 ml | | PR | PR | k.A. | | solution injectable en seringue préremplie: Nirsevimabum 100 mg/ml | Sanofi-Aventis (Suisse) SA | A | FB | | G | |
| | | | | Libmeldy | 50 ml | PR | PR | k.A. | | | SFL Pharma GmbH | A | FB | | G | |